- Home
- APGE
as of 03-06-2026 3:38pm EST
$72.11
+$1.15
+1.61%
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 4.7B | IPO Year: | 2023 |
| Target Price: | $102.40 | AVG Volume (30 days): | 799.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.22 | EPS Growth: | -27.88 |
| 52 Week Low/High: | $26.20 - $84.56 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -16.70 | Index: | N/A |
| Free Cash Flow: | -232597000.0 | FCF Growth: | N/A |
AI-Powered APGE Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 70.00%
70.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Apogee Therapeutics Inc. (APGE)
Henderson Jane
Sell
Chief Financial Officer
APGE Mar 2, 2026
Avg Cost/Share
$69.95
Shares
2,000
Total Value
$140,431.26
Owned After
181,371
Dambkowski Carl
Sell
Chief Medical Officer
APGE Feb 4, 2026
Avg Cost/Share
$66.88
Shares
5,500
Total Value
$361,860.03
Owned After
214,167
Henderson Jane
Sell
Chief Financial Officer
APGE Feb 2, 2026
Avg Cost/Share
$66.08
Shares
2,000
Total Value
$131,629.52
Owned After
181,371
Fairmount Funds Management LLC
Sell
Director
APGE Jan 22, 2026
Avg Cost/Share
$76.30
Shares
1,750,000
Total Value
$133,525,000.00
Owned After
298,647
SEC Form 4
Henderson Jane
Sell
Chief Financial Officer
APGE Jan 6, 2026
Avg Cost/Share
$80.00
Shares
2,000
Total Value
$160,000.00
Owned After
181,371
SEC Form 4
Henderson Jane
Sell
Chief Financial Officer
APGE Jan 2, 2026
Avg Cost/Share
$74.66
Shares
6,000
Total Value
$449,145.60
Owned After
181,371
Henderson Jane
Sell
Chief Financial Officer
APGE Dec 19, 2025
Avg Cost/Share
$80.00
Shares
1,500
Total Value
$120,000.00
Owned After
181,371
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Henderson Jane | APGE | Chief Financial Officer | Mar 2, 2026 | Sell | $69.95 | 2,000 | $140,431.26 | 181,371 | |
| Dambkowski Carl | APGE | Chief Medical Officer | Feb 4, 2026 | Sell | $66.88 | 5,500 | $361,860.03 | 214,167 | |
| Henderson Jane | APGE | Chief Financial Officer | Feb 2, 2026 | Sell | $66.08 | 2,000 | $131,629.52 | 181,371 | |
| Fairmount Funds Management LLC | APGE | Director | Jan 22, 2026 | Sell | $76.30 | 1,750,000 | $133,525,000.00 | 298,647 | |
| Henderson Jane | APGE | Chief Financial Officer | Jan 6, 2026 | Sell | $80.00 | 2,000 | $160,000.00 | 181,371 | |
| Henderson Jane | APGE | Chief Financial Officer | Jan 2, 2026 | Sell | $74.66 | 6,000 | $449,145.60 | 181,371 | |
| Henderson Jane | APGE | Chief Financial Officer | Dec 19, 2025 | Sell | $80.00 | 1,500 | $120,000.00 | 181,371 |
Latest Apogee Therapeutics Inc. News
APGE Breaking Stock News: Dive into APGE Ticker-Specific Updates for Smart Investing
MT Newswires
Wedbush Adjusts Price Target on Apogee Therapeutics to $95 From $90, Maintains Outperform Rating
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
📈
AI Sentiment
Highly Positive
8/10
Compare APGE vs Leading Stocks
See how APGE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "APGE Apogee Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.